中国呼吸与危重监护杂志

中国呼吸与危重监护杂志

肠杆菌社区获得性肺炎的临床特征和预后因素分析

查看全文

目的 探讨肠杆菌社区获得性肺炎(EnCAP)的临床特征和影响 30 d 病死率的因素。 方法 回顾性分析我院 2010 年至 2015 年收治的 EnCAP 237 例和肺炎链球菌社区获得性肺炎(SpCAP)120 例,比较两组的人口学、基础病、临床症状体征、相关实验室检查和影像学,以及治疗和预后。单因素分析和 Logistic 回归分析影响 EnCAP 30 d 病死率的危险因素。 结果 和 SpCAP 组相比,EnCAP 组脑血管疾病(19.8% 比 8.3%)、慢性肝病(8.4% 比 1.7%)、慢性肾病(5.1% 比 0.0%)、吸入因素(11.0% 比 0.0%)比例高,PSI 分级(2.9±1.3 比 2.5±0.8)/CURB-65 评分(1.1±0.1 比 0.6±0.4)更高;意识改变(12.2% 比 0.0%)常见,血白细胞计数[(9.5±5.7)×109/L 比(10.4±4.8)×109/L]、血红蛋白[(125.0±9.0)g/L 比(135.0±15.0)g/L]、白蛋白[(32.0±8.0)g/L 比(36.0±9.4)g/L]水平低,合并胸腔积液者(30.4% 比 12.5%)更常见;在合理经验性抗感染治疗比例接近的条件下,两者临床结局类似,但 EnCAP 住院时间更长(12.0 d 比 7.0 d)。Logistic 回归分析证实血红蛋白(OR 0.087,95%CI 0.857~0.981)、合理的经验性抗感染治疗(OR 0.108,95%CI 0.011~0.151)和脓毒性休克(OR 1.700,95%CI 0.781~38.326)是影响 EnCAP 30 d 病死率的独立危险因素。 结论 EnCAP 的临床表现不同于SpCAP。脓毒性休克是 EnCAP 30 d 死亡的独立危险因素,血红蛋白与合理的经验性抗感染治疗是保护因素,能够降低 30 d 病死率。

Objective To explore clinical characteristics and risk factors for mortality of community-acquired pneumonia due to Enterobacteriaceae (EnCAP) . Methods This was a single-center, retrospective study. Baseline demographic, clinic, radiologic characteristcs, treatment and outcomes were compared between patients hospilized with EnCAP and community-acquired pneumonia due to Streptoccocus pneumoniae (SpCAP) during January 1, 2010 to December 31, 2015. A univariate and multivariate logistic regression analysis was performed to determine factors independently associated with 30-day mortality for EnCAP. Results In comparison with SpCAP, cerebrovascular disease, chronic hepatopathy, chronic renal disease, aspiration risk, confusion, pleural effusion and higher PSI risk class/CURB-65 score, lower leukocyte, hemoglobin, albumin, longer length of stay in hospital were associated with EnCAP. Multivariate logistic regression analysis demonstrated sepsis shock (OR 1.700, P=0.018, 95%CI 0.781 to 38.326), hemoglobin (OR 0.087, P=0.011, 95%CI 0.857 to 0.981) and appropriate empirical antimicrobial therapy (OR 0.108, P=0.002, 95%CI 0.011 to 0.151) were risk factor for 30-day mortality of EnCAP. Conclusions The clinical characteristics of EnCAP are different with SpCAP. Clinic physicians should pay much attention to the risk factors for 30-day mortality of EnCAP.

关键词: 肠杆菌; 社区获得性肺炎; 临床特征; 预后

Key words: Enterobacteriaceae; Community-acquired pneumonia; Clinical characteresitics; 30-Day mortality

引用本文: 陈亮, 刘佳, 白鹭. 肠杆菌社区获得性肺炎的临床特征和预后因素分析. 中国呼吸与危重监护杂志, 2017, 16(5): 441-445. doi: 10.7507/1671-6205.201703021 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Kang CI, Kim SH, Bang JW, et al. Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci 2006, 21(5): 816-822
2. Kobashi Y, Fujita K, Karino T, et al. Clinical analysis of community-acquired pneumonia requiring hospitalization in a community hospital--comparison of elderly and non-elderly patients.Kansenshogaku Zasshi. 2000, 74(1): 43-50
3. Bansal S, Kashyap S, Pal LS, et al. Clinical and bacteriological profile of community acquired pneumonia in Shimla, Himachal Pradesh. Indian J Chest Dis Allied Sci 2004, 46(1): 17-22
4. Huang HH, Zhang YY, Xiu QY, et al. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. Eur J Clin Microbiol Infect Dis 2006, 25(6): 369-374
5. 社区获得性肺炎诊断和治疗指南(草案). 中华结核和呼吸杂志, 1999, 22(2): 199-2010
6. 中国成人社区获得性肺炎诊断和治疗指南(2016 版). 中华结核和呼吸杂志, 2016, 39(4): 241-20
7. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005, 171(4): 388–4160
8. Nakai H, Hagihara M, Kato H, et al. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producingEnterobacteriaceae.J Infect Chemother. 2016, 22(5): 319-26
9. von Baum H, Welte T, Marre R, et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors.Eur Respir J. 2010, 35(3): 598-605.
10. Rattanaumpawan P, Nachamkin I, Bilker WB, et al. Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.J Antimicrob Chemother. 2015, 70(5): 1547-1551
11. Sahuquillo-Arce JM, Menéndez R, Méndez R, et al. Age-related risk factors for bacterial aetiology in community-acquired pneumonia.Respirology. 2016, 21(8): 1472-1479
12. Ko WC, Paterson DL, Sagnimeni AJ, et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis. 2002, 8(2): 160-166.
13. ERuiz LA, Gómez A, Jaca C, et al. Bacteraemic community-acquired pneumonia due to Gram-negative bacteria: incidence, clinical presentation and factors associated with severity during hospital stay.Infection. 2010, 38(6): 453-458.
14. Kang CI, Song JH, Oh WS, et al. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli.Eur J Clin Microbiol Infect Dis. 2008, 27(8): 657-661
15. Harbarth S, Rohner P, Auckenthaler R, et al. Impact and pattern of gram-negative bacteraemia during 6 y at a large university hospital. Scand J Infect Dis. 1999, 31(2): 163-168
16. Hung IF, Zhang AJ, To KK, et al. Unexpectedly higher morbidity and mortality of hospitalized elderly patients associated with rhinovirus compared with influenza virus respiratory tract infection.Int J Mol Sci. 2017, 18(2): 259-268
17. Reade MC, Weissfeld L, Angus DC, et al. The prevalence of anemia and its association with 90-day mortality in hospitalized community-acquired pneumonia.BMC Pulm Med. 2010, 10: 15.
18. Brancati FL, Chow JW, Wagener MM, et al. Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia.Lancet. 1993, 342(8862): 30-33
19. Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004, 15;169(8): 910-914
20. Raz R, Dyachenko P, Levy Y, et al. A predictive model for the management of community-acquired pneumonia. Infection 2003, 31(1): 3-8
21. John M, Hoernig S, Doehner W, et al .Anemia and inflammation in COPD. Chest 2005, 127(3): 825-829
22. Yende S, D’Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008, 177(11): 1242-1247.
23. Askim Å, Mehl A, Paulsen J, et al. Epidemiology and outcome of sepsis in adult patients with Streptococcus pneumoniae infection in a Norwegian county 1993-2011: an observational study. BMC Infect Dis. 2016, 23;16: 223.
24. Guillamet CV, Vazquez R, Noe J, et al. A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy? Medicine (Baltimore). 2016, 95(35): e4708.
25. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015, 70(7): 2133-2143
26. Nseir S, Martin-Loeches I, Makris D, et al. Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia. Crit Care. 2014, 18(3): 129-136
27. Chang-Hua C, Li-Chen L, Yu-Jun C, et al. Mortality analysis of Enterococcus faecium bloodstream infection in central Taiwan. Rev Chilena Infectol. 2016, 33(4): 395-402
28. Bhengsri S, Lertiendumrong J, Baggett HC, et al. Economic burden of bacteremic melioidosis in eastern and northeastern, Thailand.Am J Trop Med Hyg. 2013, 89(2): 369-373
29. 冯军花, 何京, 杨青, 等. 临床分离肺炎克雷伯菌分布及耐药性分析. 中华医院感染学杂志, 2016, 26(22): 5053-50550
30. 刘朝晖, 陈劲龙, 叶惠芬, 等. 肺炎克雷伯菌社区获得性肺炎与医院获得性肺炎的比较研究. 中国呼吸与危重监护杂志, 2004, 3(5): 289-2920